Weight-loss drugs have become one of the biggest healthcare trends globally, but their adoption in India appears to be falling short of expectations. Highlighting this surprising trend, Zerodha co-founder Nithin Kamath said that despite obesity rates rising and generic versions of GLP-1 drugs becoming significantly more affordable, Indian consumers are not embracing them at the same pace as their Western counterparts.
Kamath was reacting to a report of The Economic Times that highlighted how "homegrown drugmakers, which entered the generic semaglutide market with ambitious first-year revenue goals, are quietly paring sales targets".
